Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report)'s stock price rose 7.9% during trading on Wednesday . The company traded as high as $15.44 and last traded at $15.42. Approximately 478,811 shares changed hands during mid-day trading, a decline of 64% from the average daily volume of 1,319,620 shares. The stock had previously closed at $14.29.
Ginkgo Bioworks Price Performance
The stock has a fifty day moving average price of $10.95.
Institutional Trading of Ginkgo Bioworks
Several institutional investors have recently added to or reduced their stakes in the business. SBI Securities Co. Ltd. purchased a new stake in Ginkgo Bioworks in the fourth quarter worth $29,000. KBC Group NV purchased a new position in shares of Ginkgo Bioworks during the 4th quarter worth $31,000. Palumbo Wealth Management LLC bought a new position in shares of Ginkgo Bioworks during the 4th quarter valued at approximately $144,000. Y Intercept Hong Kong Ltd bought a new position in Ginkgo Bioworks in the 4th quarter worth $154,000. Finally, SVB Wealth LLC purchased a new stake in Ginkgo Bioworks during the 4th quarter valued at approximately $171,000. 78.63% of the stock is currently owned by hedge funds and other institutional investors.
Ginkgo Bioworks Company Profile
(
Get Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Featured Stories
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
